Results 91 to 100 of about 2,198,265 (159)

Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx)

Cardiology and Therapy
Introduction Tafamidis is the first drug approved by the European Commission for the treatment of wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related ...
Sepideh Attal, Jason Kemner, Jose Alvir, Sebastian Barth, Sofia Schuessler   +4 more
doaj   +1 more source

Living with Transthyretin amyloid cardiomyopathy from a patient perspective

BMC Cardiovascular Disorders
Background Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive condition for which disease-modifying therapies are increasingly available. However, limited research has explored the patient experience with ATTR-CM and its impact on quality of
Quan M. Bui, Julia McCain, Larry A. Allen, Eric D. Adler, Cheryl Anderson, Cinnamon Bloss, Borsika A. Rabin, Marcus A. Urey   +7 more
doaj   +1 more source

Efficacy of Tafamidis in Transthyretin Amyloid Cardiomyopathy in the ATTR-ACT Trial: Sensitivity Analyses Further Support the Primary Results

, 2018
Transthyretin cardiomyopathy (ATTR-CM) is an underdiagnosed, fatal disease caused by the deposition of transthyretin amyloid fibrils in the heart leading to heart failure (HF).
Maurer, Mathew S, Merlini, Giampaolo, Rapezzi, Claudio, Patterson, Terrell A, Elliott, Perry, Berk, John L, Gundapaneni, Balarama, Velazquez, Eric J, Damy, Thibaud, Shah, Sanjiv J, Witteles, Ronald, Sultan, Marla B, Schwartz, Jeffrey H, Cruz, Márcia Waddington, Judge, Daniel P, Drachman, Brian M, Hanna, Mazen, Lenihan, Daniel J, Kristen, Arnt V, Hoffman, James E, Gottlieb, Stephen S, Hummel, Scott L, Grogan, Martha   +22 more
core   +1 more source

Tafamidis therapy in transthyretin amyloid cardiomyopathy: a narrative review from clinical trials and real-world evidence

The Egyptian Heart Journal
Background Amyloidosis is a heterogeneous group of disorders caused by the extracellular deposition of insoluble misfolded proteins, leading to end-organ damage.
Ikponmwosa Jude Ogieuhi, Oshomoh Mark-Anthony Ugiomoh, Kudzaishe Muzofa, Kristen Callender, Johnson David Ayodeji, Nnokam Prayer Nnekachi, Barkavi Thiyagarajan, Emmanuel Obokhai Uduigwome, Abhay Kapoor, Moses Chukwuebuka Odoeke, Reem Gamaleldin Hassan Mohamed, Courage Idahor   +11 more
doaj   +1 more source

Survival in a Contemporary, Real-World Cohort of Patients with Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: An Analysis from THAOS

Cardiology and Therapy
Introduction Tafamidis is approved to treat transthyretin amyloid cardiomyopathy (ATTR-CM). Many patients with ATTR-CM present with a mixed phenotype of both cardiac and neurologic symptoms, but real-world effectiveness studies of tafamidis in this ...
Jonas Wixner, Angela Dispenzieri, Leslie Amass, Martin Carlsson, Steve Riley, Evan Powers, Jeffery W. Kelly, the THAOS investigators   +7 more
doaj   +1 more source

Bone Tracers for Transthyretin Amyloid Cardiomyopathy: Are [Tc]Tc-DPD and [Tc]Tc-HMDP Equivalent?

Molecular Imaging
The management of transthyretin amyloid cardiomyopathy (ATTR-CM) has revolved around the scintigraphic diagnosis since the introduction of a specific treatment; however, the equivalency of the bone radiotracers remains unclear.
Julien Dubois PharmD, PhD Student, Florentin Kucharczak MD, PhD, Denis Mariano-Goulart MD, PhD, Tom Paunet MD   +3 more
doaj   +1 more source

Transferability of a US claims-based machine learning model for ATTRwt-CM identification: a retrospective evaluation in a German setting

Scientific Reports
Cardiac amyloidosis (CA), a fatal and progressive cardiomyopathy is characterized by amyloid deposition within the myocardium. The main forms of CA include transthyretin amyloidosis (ATTR-CM; distinguished into a hereditary and wildtype form [ATTRv and ...
Harisa Muratovic-Colic, Miriam R. Hübner, Jan-Filip Rehburg, Isabel Mattig, Paul J. Wetzel, Katrin Wrede-Wihl, Helena F. Pernice, Gina Barzen, Nicolas Wieder, Jakub Piwowarski, Stephan Bohl, Vera von Landenberg-Roberg, Daniel Messroghli, Sebastian Spethmann, Richard Röttger, Josef Schepers, Katrin Hahn   +16 more
doaj   +1 more source

Three-dimensional echocardiographic assessment of right ventricular global myocardial work and ventricular–pulmonary coupling in ATTR cardiac amyloidosis

Background: Right ventricular (RV) function is inadequately investigated and routinely overlooked in transthyretin amyloid cardiomyopathy (ATTR-CM). Novel imaging distinguishers between intrinsic RV myocardial disease in ATTR-CM and primary RV overload ...
Venkateshvaran, Ashwin, Kovacs, Attila,, Ashwin Venkateshvaran, Kovacs, Attila, Attila Kovacs, Fredrik Edbom, Edbom, Fredrik,, Per Lindqvist, Arvidsson, Sandra, Lindqvist, Per,, Sandra Arvidsson, Venkateshvaran, Ashwin,, Arvidsson, Sandra,, Lindqvist, Per, Edbom, Fredrik   +14 more
core   +1 more source

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy

Cardiology and Therapy
Introduction Transthyretin amyloidosis (ATTR) is a progressive, heterogeneous rare disease manifesting as ATTR polyneuropathy (ATTR-PN), ATTR cardiomyopathy (ATTR-CM), or a mixed phenotype. Tafamidis meglumine (20 mg po qd) is approved in some markets to
Nicholas Streicher, Leslie Amass, Rong Wang, Jennifer M. Stephens, Traci LeMasters, Rutika Raina, Emma Merrill, Farooq H. Sheikh   +7 more
doaj   +1 more source

Detecting transthyretin amyloid cardiomyopathy (ATTR-CM) using machine learning: an evaluation of the performance of an algorithm in a UK setting. [PDF]

BMJ Open, 2023
Tsang C, Huda A, Norman M, Dickerson C, Leo V, Brownrigg J, Mamas M, Elliott P.   +7 more
europepmc   +1 more source